Holen Sie sich die Stockscreener-App
10.97
0.27%
-0.03
Handel nachbörslich:
10.97
Schlusskurs vom Vortag:
$11.00
Offen:
$11.03
24-Stunden-Volumen:
607.06K
Relative Volume:
0.72
Marktkapitalisierung:
$701.65M
Einnahmen:
$262.60M
Nettoeinkommen (Verlust:
$-80.80M
KGV:
-9.0206
EPS:
-1.2161
Netto-Cashflow:
$-275.70M
1W Leistung:
-2.14%
1M Leistung:
-9.93%
6M Leistung:
+15.96%
1J Leistung:
+44.72%
1-Tages-Spanne:
$10.64
$11.05
1-Wochen-Bereich:
$10.56
$11.47
52-Wochen-Spanne:
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
10.97 | 703.57M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Treasury Yields: Can Arvinas Inc outperform in the next rally2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Why (ARVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN - MarketBeat
Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance Australia
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas, Inc. (ARVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach - Yahoo Finance
ARVN Technical Analysis & Stock Price Forecast - Intellectia AI
Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat
Arvinas Shares Surge 6.9% on Positive Pipeline Expectations - Intellectia AI
Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained? - Bitget
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last? - Yahoo Finance
Pullback Watch: Can Arvinas Inc ride the EV waveMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Arvinas (ARVN) price target increased by 13.60% to 15.54 - MSN
Aug Summary: How does Arvinas Inc correlate with Nasdaq2026 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Vanguard realignment leaves Arvinas (ARVN) ownership listed as 0 shares - Stock Titan
Arvinas patents new PROTACs for the degradation of BCL-6 - bioworld.com
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aug EndMonth: Is Arvinas Inc in a bullish channelMarket Growth Review & Weekly Breakout Watchlists - baoquankhu1.vn
ARVN PE Ratio & Valuation, Is ARVN Overvalued - Intellectia AI
H.C. Wainwright reiterates Arvinas stock rating on trial data - Investing.com UK
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS), High Tide (HITI) and Arvinas Holding Company (ARVN) - The Globe and Mail
H.C. Wainwright reiterates Arvinas stock rating on trial data By Investing.com - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX) - The Globe and Mail
Arvinas’ chief medical officer Berkowitz sells $71k in shares By Investing.com - Investing.com South Africa
Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Arvinas’ chief medical officer Berkowitz sells $71k in shares - Investing.com UK
Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale - Stock Titan
Tranche Update on Arvinas, Inc.'s Equity Buyback Plan announced on September 17, 2025. - marketscreener.com
Arvinas (ARVN): Citigroup Raises Price Target to $21.00 and Main - GuruFocus
Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
BTIG Analyst Raises Price Target for Arvinas (ARVN) to $16 | ARV - GuruFocus
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 By Investing.com - Investing.com South Africa
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 - Investing.com India
BTIG raises Arvinas stock price target on positive trial data By Investing.com - Investing.com Australia
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
BTIG raises Arvinas stock price target on positive trial data - Investing.com
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas - TipRanks
Arvinas (ARVN) Reports Promising Phase 1 Trial Results for ARV-102 in Parkinson's Disease - GuruFocus
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data By Investing.com - Investing.com Australia
Arvinas, Inc. Reports Forward-Looking Statements and Updates on ARV-102 Neurodegenerative Disease Program – March 2026 - Minichart
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):